{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:05:26Z","timestamp":1794344726344,"version":"4.9.0"},"reference-count":313,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41568-025-00905-9","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:27:28Z","timestamp":1768566448000},"page":"285-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0025-3668","authenticated-orcid":false,"given":"Frank","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annachiara","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7826-3888","authenticated-orcid":false,"given":"Mara H.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"905_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"905_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P., Sunkara, T. & Gaduputi, V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J. Oncol. 10, 10\u201327 (2019).","journal-title":"World J. Oncol."},{"key":"905_CR3","unstructured":"National Institutes of Health Surveillance, National Cancer Institute. Epidemiology and End Results Program. Cancer Stat Facts: Pancreatic Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html (2023)."},{"key":"905_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-024-07359-3","volume":"629","author":"AM Braxton","year":"2024","unstructured":"Braxton, A. M. et al. 3D genomic mapping reveals multifocality of human pancreatic precancers. Nature 629, 679\u2013687 (2024).","journal-title":"Nature"},{"key":"905_CR5","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1158\/2159-8290.CD-23-0013","volume":"13","author":"ES Carpenter","year":"2023","unstructured":"Carpenter, E. S. et al. Analysis of donor pancreata defines the transcriptomic signature and microenvironment of early neoplastic lesions. Cancer Discov. 13, 1324\u20131345 (2023). This study was the first comprehensive molecular and cellular analysis of normal human pancreas tissue, providing both a demonstration of pervasive pre-invasive lesions in these tissues and characterization of the fibroinflammatory niches associated with these lesions.","journal-title":"Cancer Discov."},{"key":"905_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/bs.pmbts.2016.09.008","volume":"144","author":"TJ Grant","year":"2016","unstructured":"Grant, T. J., Hua, K. & Singh, A. Molecular pathogenesis of pancreatic cancer. Prog. Mol. Biol. Transl. Sci. 144, 241\u2013275 (2016).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"905_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469\u2013483 (2005).","journal-title":"Cancer Cell"},{"key":"905_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1101\/gad.275776.115","volume":"30","author":"H Ying","year":"2016","unstructured":"Ying, H. et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 30, 355\u2013385 (2016).","journal-title":"Genes Dev."},{"key":"905_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13040655","author":"MJ Amaral","year":"2023","unstructured":"Amaral, M. J. et al. Tumor stroma area and other prognostic factors in pancreatic ductal adenocarcinoma patients submitted to surgery. Diagnostics https:\/\/doi.org\/10.3390\/diagnostics13040655 (2023).","journal-title":"Diagnostics"},{"key":"905_CR10","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1101\/gad.348523.121","volume":"35","author":"GL Beatty","year":"2021","unstructured":"Beatty, G. L., Werba, G., Lyssiotis, C. A. & Simeone, D. M. The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes Dev. 35, 940\u2013962 (2021).","journal-title":"Genes Dev."},{"key":"905_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman, M. H. & Beatty, G. L. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu. Rev. Pathol. 18, 123\u2013148 (2023).","journal-title":"Annu. Rev. Pathol."},{"key":"905_CR12","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","volume":"184","author":"BT Gr\u00fcnwald","year":"2021","unstructured":"Gr\u00fcnwald, B. T. et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell 184, 5577\u20135592.e18 (2021).","journal-title":"Cell"},{"key":"905_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/science.add5327","author":"C Burdziak","year":"2023","unstructured":"Burdziak, C. et al. Epigenetic plasticity cooperates with cell\u2013cell interactions to direct pancreatic tumorigenesis. Science https:\/\/doi.org\/10.1126\/science.add5327 (2023).","journal-title":"Science"},{"key":"905_CR14","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1158\/0008-5472.CAN-24-1926","volume":"84","author":"AJ Aguirre","year":"2024","unstructured":"Aguirre, A. J., Stanger, B. Z. & Maitra, A. Hope on the horizon: a revolution in KRAS inhibition is creating a new treatment paradigm for patients with pancreatic cancer. Cancer Res. 84, 2950\u20132953 (2024).","journal-title":"Cancer Res."},{"key":"905_CR15","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1158\/2159-8290.CD-19-0597","volume":"10","author":"P Hou","year":"2020","unstructured":"Hou, P. et al. Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer. Cancer Discov. 10, 1058\u20131077 (2020).","journal-title":"Cancer Discov."},{"key":"905_CR16","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","volume":"184","author":"S Raghavan","year":"2021","unstructured":"Raghavan, S. et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell 184, 6119\u20136137.e26 (2021).","journal-title":"Cell"},{"key":"905_CR17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-1475","author":"MI Orlen","year":"2025","unstructured":"Orlen, M. I. et al. T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1475 (2025).","journal-title":"Cancer Discov."},{"key":"905_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1172\/JCI59227","volume":"122","author":"MA Collins","year":"2012","unstructured":"Collins, M. A. et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 122, 639\u2013653 (2012).","journal-title":"J. Clin. Invest."},{"key":"905_CR19","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jcmgh.2022.02.016","volume":"13","author":"A Velez-Delgado","year":"2022","unstructured":"Velez-Delgado, A. et al. Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming. Cell. Mol. Gastroenterol. Hepatol. 13, 1673\u20131699 (2022).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"905_CR20","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1158\/2159-8290.CD-24-0100","volume":"14","author":"KL Donahue","year":"2024","unstructured":"Donahue, K. L. et al. Oncogenic KRAS-dependent stromal interleukin-33 directs the pancreatic microenvironment to promote tumor growth. Cancer Discov. 14, 1964\u20131989 (2024).","journal-title":"Cancer Discov."},{"key":"905_CR21","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan, K. K. et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell 41, 1606\u20131620.e8 (2023). This study showed that KRAS inhibition promotes antitumour responses in PDAC at least in part via CD8+ T cell cytotoxicity, potentially as a consequence of tumour cell apoptosis.","journal-title":"Cancer Cell"},{"key":"905_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1152\/physiolgenomics.00158.2013","volume":"46","author":"B Rybinski","year":"2014","unstructured":"Rybinski, B., Franco-Barraza, J. & Cukierman, E. The wound healing, chronic fibrosis, and cancer progression triad. Physiol. Genom. 46, 223\u2013244 (2014).","journal-title":"Physiol. Genom."},{"key":"905_CR23","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1158\/2159-8290.CD-20-0841","volume":"11","author":"SM Liudahl","year":"2021","unstructured":"Liudahl, S. M. et al. Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: phenotypic and spatial features associated with clinical outcome. Cancer Discov. 11, 2014\u20132031 (2021). This study was the first comprehensive in situ analysis of immune cell phenotypic and spatial properties in human PDAC and reports associations between diverse features of immune contexture and patient outcomes.","journal-title":"Cancer Discov."},{"key":"905_CR24","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1158\/0008-5472.CAN-22-1190","volume":"82","author":"H Mi","year":"2022","unstructured":"Mi, H. et al. Quantitative spatial profiling of immune populations in pancreatic ductal adenocarcinoma reveals tumor microenvironment heterogeneity and prognostic biomarkers. Cancer Res. 82, 4359\u20134372 (2022).","journal-title":"Cancer Res."},{"key":"905_CR25","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1158\/2326-6066.CIR-16-0322","volume":"5","author":"IM Stromnes","year":"2017","unstructured":"Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D. & Hingorani, S. R. T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma. Cancer Immunol. Res. 5, 978\u2013991 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"905_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","volume":"551","author":"VP Balachandran","year":"2017","unstructured":"Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512\u2013516 (2017).","journal-title":"Nature"},{"key":"905_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","volume":"49","author":"J Li","year":"2018","unstructured":"Li, J. et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity 49, 178\u2013193.e7 (2018).","journal-title":"Immunity"},{"key":"905_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao, Z. et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat. Commun. 14, 5110 (2023). This study implicated the FAP+ sub-population of PDAC CAFs as tumour-promoting and immune-suppressive and demonstrated safety and efficacy of targeting FAP-expressing cells in preclinical models.","journal-title":"Nat. Commun."},{"key":"905_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-245","volume":"11","author":"HO Lee","year":"2011","unstructured":"Lee, H. O. et al. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 11, 245 (2011).","journal-title":"BMC Cancer"},{"key":"905_CR30","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1158\/2159-8290.CD-22-1046","volume":"13","author":"A Bianchi","year":"2023","unstructured":"Bianchi, A. et al. Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer. Cancer Discov. 13, 1428\u20131453 (2023).","journal-title":"Cancer Discov."},{"key":"905_CR31","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41590-024-01820-1","volume":"25","author":"ML Stone","year":"2024","unstructured":"Stone, M. L. et al. Hepatocytes coordinate immune evasion in cancer via release of serum amyloid A proteins. Nat. Immunol. 25, 755\u2013763 (2024).","journal-title":"Nat. Immunol."},{"key":"905_CR32","doi-asserted-by":"publisher","first-page":"eadh9562","DOI":"10.1126\/scitranslmed.adh9562","volume":"15","author":"Z Meng","year":"2023","unstructured":"Meng, Z. et al. Transcriptome-based identification of tumor-reactive and bystander CD8(+) T cell receptor clonotypes in human pancreatic cancer. Sci. Transl. Med. 15, eadh9562 (2023).","journal-title":"Sci. Transl. Med."},{"key":"905_CR33","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1158\/1078-0432.CCR-23-1444","volume":"30","author":"LR Ali","year":"2024","unstructured":"Ali, L. R. et al. PD-1 blockade induces reactivation of nonproductive T-cell responses characterized by NF-\u03baB signaling in patients with pancreatic cancer. Clin. Cancer Res. 30, 542\u2013553 (2024).","journal-title":"Clin. Cancer Res."},{"key":"905_CR34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023). This study demonstrated the feasibility of personalized RNA neoantigen vaccination for patients with PDAC and the possibility that these vaccines may stimulate T cell responses in patients.","journal-title":"Nature"},{"key":"905_CR35","doi-asserted-by":"publisher","first-page":"eadk3487","DOI":"10.1126\/science.adk3487","volume":"388","author":"ZA Ely","year":"2025","unstructured":"Ely, Z. A. et al. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Science 388, eadk3487 (2025). This study was the first analysis of the specificity and immunogenicity of peptides from the non-coding genome in PDAC and demonstrates that frequent cryptic peptides can be found within the human PDAC immunopeptidome.","journal-title":"Science"},{"key":"905_CR36","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612\u20131616 (2011).","journal-title":"Science"},{"key":"905_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.151593","author":"AL Burrack","year":"2022","unstructured":"Burrack, A. L. et al. Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+\u2009T cells in pancreatic cancer. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.151593 (2022).","journal-title":"JCI Insight"},{"key":"905_CR38","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.80721","author":"RE Menjivar","year":"2023","unstructured":"Menjivar, R. E. et al. Arginase 1 is a key driver of immune suppression in pancreatic cancer. eLife https:\/\/doi.org\/10.7554\/eLife.80721 (2023).","journal-title":"eLife"},{"key":"905_CR39","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s43018-024-00731-2","volume":"5","author":"Y Astuti","year":"2024","unstructured":"Astuti, Y. et al. Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis. Nat. Cancer 5, 774\u2013790 (2024).","journal-title":"Nat. Cancer"},{"key":"905_CR40","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41590-023-01642-7","volume":"24","author":"SE Di Carlo","year":"2023","unstructured":"Di Carlo, S. E. et al. Depletion of slow-cycling PDGFR\u03b1+ADAM12+ mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis. Nat. Immunol. 24, 1867\u20131878 (2023).","journal-title":"Nat. Immunol."},{"key":"905_CR41","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212\u201320217 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"905_CR42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","volume":"611","author":"AT Krishnamurty","year":"2022","unstructured":"Krishnamurty, A. T. et al. LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature 611, 148\u2013154 (2022).","journal-title":"Nature"},{"key":"905_CR43","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1158\/2159-8290.CD-23-0428","volume":"14","author":"JI Belle","year":"2024","unstructured":"Belle, J. I. et al. Senescence defines a distinct subset of myofibroblasts that orchestrates immunosuppression in pancreatic cancer. Cancer Discov. 14, 1324\u20131355 (2024).","journal-title":"Cancer Discov."},{"key":"905_CR44","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.ccell.2021.06.017","volume":"39","author":"C Hutton","year":"2021","unstructured":"Hutton, C. et al. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. Cancer Cell 39, 1227\u20131244.e20 (2021).","journal-title":"Cancer Cell"},{"key":"905_CR45","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.devcel.2023.07.025","volume":"58","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan, K. K. et al. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Dev. Cell 58, 1562\u20131577.e68 (2023).","journal-title":"Dev. Cell"},{"key":"905_CR46","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1158\/2159-8290.CD-19-0435","volume":"10","author":"NM Sodir","year":"2020","unstructured":"Sodir, N. M. et al. MYC instructs and maintains pancreatic adenocarcinoma phenotype. Cancer Discov. 10, 588\u2013607 (2020).","journal-title":"Cancer Discov."},{"key":"905_CR47","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1158\/2159-8290.CD-22-0661","volume":"12","author":"J Abrego","year":"2022","unstructured":"Abrego, J. et al. A cancer cell-intrinsic GOT2-PPARdelta axis suppresses antitumor immunity. Cancer Discov. 12, 2414\u20132433 (2022).","journal-title":"Cancer Discov."},{"key":"905_CR48","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","volume":"606","author":"M Luksza","year":"2022","unstructured":"Luksza, M. et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature 606, 389\u2013395 (2022).","journal-title":"Nature"},{"key":"905_CR49","doi-asserted-by":"publisher","first-page":"eadh4567","DOI":"10.1126\/science.adh4567","volume":"384","author":"KK Mahadevan","year":"2024","unstructured":"Mahadevan, K. K. et al. Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Science 384, eadh4567 (2024).","journal-title":"Science"},{"key":"905_CR50","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1158\/2326-6066.CIR-21-0946","volume":"11","author":"CA James","year":"2023","unstructured":"James, C. A. et al. Systemic alterations in type-2 conventional dendritic cells lead to impaired tumor immunity in pancreatic cancer. Cancer Immunol. Res. 11, 1055\u20131067 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"905_CR51","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","volume":"37","author":"S Hegde","year":"2020","unstructured":"Hegde, S. et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell 37, 289\u2013307.e9 (2020). This study was the first functional demonstration that DC abundance is limiting in the pancreatic TME and that restoration of DC function has the potential to activate tumour-restraining immune responses.","journal-title":"Cancer Cell"},{"key":"905_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09188-4","author":"Y Dai","year":"2025","unstructured":"Dai, Y. et al. Humoral determinants of checkpoint immunotherapy. Nature https:\/\/doi.org\/10.1038\/s41586-025-09188-4 (2025).","journal-title":"Nature"},{"key":"905_CR53","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.xcrm.2022.100744","volume":"3","author":"B Mirlekar","year":"2022","unstructured":"Mirlekar, B. et al. Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell Rep. Med. 3, 100744 (2022).","journal-title":"Cell Rep. Med."},{"key":"905_CR54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","volume":"610","author":"S Li","year":"2022","unstructured":"Li, S. et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 610, 373\u2013380 (2022).","journal-title":"Nature"},{"key":"905_CR55","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"905_CR56","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/bjc.2015.145","volume":"112","author":"N Hiraoka","year":"2015","unstructured":"Hiraoka, N. et al. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br. J. Cancer 112, 1782\u20131790 (2015).","journal-title":"Br. J. Cancer"},{"key":"905_CR57","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41586-024-08426-5","volume":"638","author":"M Amisaki","year":"2025","unstructured":"Amisaki, M. et al. IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer. Nature 638, 1076\u20131084 (2025).","journal-title":"Nature"},{"key":"905_CR58","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-20-3141","volume":"27","author":"SA V\u00e4yrynen","year":"2021","unstructured":"V\u00e4yrynen, S. A. et al. Composition, spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer. Clin. Cancer Res. 27, 1069\u20131081 (2021).","journal-title":"Clin. Cancer Res."},{"key":"905_CR59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","volume":"58","author":"CM Diaz-Montero","year":"2009","unstructured":"Diaz-Montero, C. M. et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49\u201359 (2009).","journal-title":"Cancer Immunol. Immunother."},{"key":"905_CR60","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.celrep.2017.03.037","volume":"19","author":"T Tsujikawa","year":"2017","unstructured":"Tsujikawa, T. et al. Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. Cell Rep. 19, 203\u2013217 (2017).","journal-title":"Cell Rep."},{"key":"905_CR61","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s43018-020-00121-4","volume":"1","author":"NG Steele","year":"2020","unstructured":"Steele, N. G. et al. Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer. Nat. Cancer 1, 1097\u20131112 (2020).","journal-title":"Nat. Cancer"},{"key":"905_CR62","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.78921","author":"I de Castro Silva","year":"2022","unstructured":"de Castro Silva, I. et al. Neutrophil-mediated fibroblast-tumor cell IL-6\/STAT-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: a hybrid clinical-preclinical study. eLife https:\/\/doi.org\/10.7554\/eLife.78921 (2022).","journal-title":"eLife"},{"key":"905_CR63","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s43018-023-00703-y","volume":"5","author":"S Bhattacharyya","year":"2024","unstructured":"Bhattacharyya, S. et al. Autotaxin-lysolipid signaling suppresses a CCL11-eosinophil axis to promote pancreatic cancer progression. Nat. Cancer 5, 283\u2013298 (2024).","journal-title":"Nat. Cancer"},{"key":"905_CR64","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.immuni.2017.07.014","volume":"47","author":"Y Zhu","year":"2017","unstructured":"Zhu, Y. et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity 47, 323\u2013338.e6 (2017). This study defined the contributions of distinct tissue origin to the heterogeneous TAM population in PDAC and ascribed functional importance to TAMs of an embryonic or tissue-resident origin.","journal-title":"Immunity"},{"key":"905_CR65","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/s41590-023-01579-x","volume":"24","author":"JM Baer","year":"2023","unstructured":"Baer, J. M. et al. Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. Nat. Immunol. 24, 1443\u20131457 (2023).","journal-title":"Nat. Immunol."},{"key":"905_CR66","doi-asserted-by":"publisher","first-page":"eadk3981","DOI":"10.1126\/sciimmunol.adk3981","volume":"9","author":"G Dunsmore","year":"2025","unstructured":"Dunsmore, G. et al. Timing and location dictate monocyte fate and their transition to tumor-associated macrophages. Sci. Immunol. 9, eadk3981 (2025). In this study, the authors performed fate-mapping and detailed molecular analysis of the monocyte-to-TAM transition during PDAC progression, indicating phenotypic and functional heterogeneity as outcomes of this transition.","journal-title":"Sci. Immunol."},{"key":"905_CR67","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/0008-5472.CAN-19-2080","volume":"80","author":"S Das","year":"2020","unstructured":"Das, S., Shapiro, B., Vucic, E. A., Vogt, S. & Bar-Sagi, D. Tumor cell-derived IL1\u03b2 promotes desmoplasia and immune suppression in pancreatic cancer. Cancer Res. 80, 1088\u20131101 (2020).","journal-title":"Cancer Res."},{"key":"905_CR68","doi-asserted-by":"publisher","first-page":"eadp0684","DOI":"10.1126\/sciadv.adp0684","volume":"10","author":"NRJ Thielman","year":"2024","unstructured":"Thielman, N. R. J. et al. Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming. Sci. Adv. 10, eadp0684 (2024).","journal-title":"Sci. Adv."},{"key":"905_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30392-7","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPAR\u03b4. Nat. Commun. 13, 2665 (2022).","journal-title":"Nat. Commun."},{"key":"905_CR70","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","volume":"76","author":"X Yang","year":"2016","unstructured":"Yang, X. et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3\u2013CCL2 signaling. Cancer Res. 76, 4124\u20134135 (2016).","journal-title":"Cancer Res."},{"key":"905_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01388-7","volume":"22","author":"Z Hussain","year":"2024","unstructured":"Hussain, Z. et al. Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer. Cell Commun. Signal. 22, 1 (2024).","journal-title":"Cell Commun. Signal."},{"key":"905_CR72","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neo.2016.01.005","volume":"18","author":"E Mathew","year":"2016","unstructured":"Mathew, E. et al. Mesenchymal stem cells promote pancreatic tumor growth by inducing alternative polarization of macrophages. Neoplasia 18, 142\u2013151 (2016).","journal-title":"Neoplasia"},{"key":"905_CR73","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-023-06685-2","volume":"623","author":"N Caronni","year":"2023","unstructured":"Caronni, N. et al. IL-1\u03b2+\u2009macrophages fuel pathogenic inflammation in pancreatic cancer. Nature 623, 415\u2013422 (2023).","journal-title":"Nature"},{"key":"905_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00660-4","volume":"8","author":"C Wei","year":"2024","unstructured":"Wei, C. et al. Tumor-associated macrophage clusters linked to immunotherapy in a pan-cancer census. npj Precis. Oncol. 8, 176 (2024).","journal-title":"npj Precis. Oncol."},{"key":"905_CR75","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41467-023-36296-4","volume":"14","author":"G Werba","year":"2023","unstructured":"Werba, G. et al. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat. Commun. 14, 797 (2023).","journal-title":"Nat. Commun."},{"key":"905_CR76","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.celrep.2018.03.131","volume":"23","author":"JB Candido","year":"2018","unstructured":"Candido, J. B. et al. CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Rep. 23, 1448\u20131460 (2018).","journal-title":"Cell Rep."},{"key":"905_CR77","doi-asserted-by":"publisher","first-page":"112732","DOI":"10.1016\/j.celrep.2023.112732","volume":"42","author":"MT Patterson","year":"2023","unstructured":"Patterson, M. T. et al. Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma. Cell Rep. 42, 112732 (2023).","journal-title":"Cell Rep."},{"key":"905_CR78","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu, Y. et al. CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74, 5057\u20135069 (2014).","journal-title":"Cancer Res."},{"key":"905_CR79","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/s43018-022-00470-2","volume":"3","author":"F Cappellesso","year":"2022","unstructured":"Cappellesso, F. et al. Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. Nat. Cancer 3, 1464\u20131483 (2022).","journal-title":"Nat. Cancer"},{"key":"905_CR80","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","volume":"55","author":"K Hezaveh","year":"2022","unstructured":"Hezaveh, K. et al. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. Immunity 55, 324\u2013340.e8 (2022).","journal-title":"Immunity"},{"key":"905_CR81","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1158\/0008-5472.CAN-20-3929","volume":"81","author":"SB Kemp","year":"2021","unstructured":"Kemp, S. B. et al. Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-\u03baB-mediated production of CXCL1. Cancer Res. 81, 4305\u20134318 (2021).","journal-title":"Cancer Res."},{"key":"905_CR82","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1136\/gutjnl-2021-325564","volume":"72","author":"M Alonso-Nocelo","year":"2023","unstructured":"Alonso-Nocelo, M. et al. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Gut 72, 345\u2013359 (2023).","journal-title":"Gut"},{"key":"905_CR83","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s42003-024-06087-8","volume":"7","author":"K Boelaars","year":"2024","unstructured":"Boelaars, K. et al. Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions. Commun. Biol. 7, 430 (2024).","journal-title":"Commun. Biol."},{"key":"905_CR84","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/gutjnl-2020-322744","volume":"71","author":"X Sun","year":"2022","unstructured":"Sun, X. et al. Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. Gut 71, 129\u2013147 (2022).","journal-title":"Gut"},{"key":"905_CR85","doi-asserted-by":"publisher","first-page":"17412","DOI":"10.1038\/s41598-024-68109-z","volume":"14","author":"E Li","year":"2024","unstructured":"Li, E., Cheung, H. C. Z. & Ma, S. CTHRC1+ fibroblasts and SPP1+ macrophages synergistically contribute to pro-tumorigenic tumor microenvironment in pancreatic ductal adenocarcinoma. Sci. Rep. 14, 17412 (2024).","journal-title":"Sci. Rep."},{"key":"905_CR86","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2119168119","volume":"119","author":"MM LaRue","year":"2022","unstructured":"LaRue, M. M. et al. Metabolic reprogramming of tumor-associated macrophages by collagen turnover promotes fibrosis in pancreatic cancer. Proc. Natl Acad. Sci. USA 119, e2119168119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"905_CR87","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/ncb3340","volume":"18","author":"SR Nielsen","year":"2016","unstructured":"Nielsen, S. R. et al. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nat. Cell Biol. 18, 549\u2013560 (2016).","journal-title":"Nat. Cell Biol."},{"key":"905_CR88","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1158\/0008-5472.CAN-17-3876","volume":"78","author":"V Quaranta","year":"2018","unstructured":"Quaranta, V. et al. Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer. Cancer Res. 78, 4253\u20134269 (2018).","journal-title":"Cancer Res."},{"key":"905_CR89","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41590-018-0292-y","volume":"20","author":"M Liu","year":"2019","unstructured":"Liu, M. et al. Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated \u2018don\u2019t-eat-me\u2019 signal. Nat. Immunol. 20, 265\u2013275 (2019).","journal-title":"Nat. Immunol."},{"key":"905_CR90","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf5058","author":"K Roehle","year":"2021","unstructured":"Roehle, K. et al. cIAP1\/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abf5058 (2021).","journal-title":"Sci. Transl. Med."},{"key":"905_CR91","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190673","author":"JH Lin","year":"2020","unstructured":"Lin, J. H. et al. Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20190673 (2020).","journal-title":"J. Exp. Med."},{"key":"905_CR92","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/00006676-200401000-00023","volume":"28","author":"A Fukunaga","year":"2004","unstructured":"Fukunaga, A. et al. CD8+\u2009tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28, e26\u2013e31 (2004).","journal-title":"Pancreas"},{"key":"905_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051216","author":"I Plesca","year":"2022","unstructured":"Plesca, I. et al. Clinical significance of tumor-infiltrating conventional and plasmacytoid dendritic cells in pancreatic ductal adenocarcinoma. Cancers https:\/\/doi.org\/10.3390\/cancers14051216 (2022).","journal-title":"Cancers"},{"key":"905_CR94","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41467-018-03600-6","volume":"9","author":"MA Meyer","year":"2018","unstructured":"Meyer, M. A. et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat. Commun. 9, 1250 (2018).","journal-title":"Nat. Commun."},{"key":"905_CR95","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022\u20131037.e14 (2018).","journal-title":"Cell"},{"key":"905_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14970-0","volume":"7","author":"J Markowitz","year":"2017","unstructured":"Markowitz, J. et al. Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+\u2009T cells in cancer and measurement of STAT1 nitration. Sci. Rep. 7, 15424 (2017).","journal-title":"Sci. Rep."},{"key":"905_CR97","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.immuni.2016.08.015","volume":"45","author":"M Guilliams","year":"2016","unstructured":"Guilliams, M. et al. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity 45, 669\u2013684 (2016).","journal-title":"Immunity"},{"key":"905_CR98","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102\u20131123 (2019).","journal-title":"Cancer Discov."},{"key":"905_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09416-2","volume":"10","author":"RM Barilla","year":"2019","unstructured":"Barilla, R. M. et al. Specialized dendritic cells induce tumor-promoting IL-10+IL-17+FoxP3neg regulatory CD4+ T cells in pancreatic carcinoma. Nat. Commun. 10, 1424 (2019).","journal-title":"Nat. Commun."},{"key":"905_CR100","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.celrep.2017.06.062","volume":"20","author":"J-E Jang","year":"2017","unstructured":"Jang, J.-E. et al. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep. 20, 558\u2013571 (2017).","journal-title":"Cell Rep."},{"key":"905_CR101","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1158\/0008-5472.CAN-24-0830","volume":"84","author":"K Oyama","year":"2024","unstructured":"Oyama, K. et al. Combined autophagy inhibition and dendritic cell recruitment induces antitumor immunity and enhances immune checkpoint blockade sensitivity in pancreatic cancer. Cancer Res. 84, 4214\u20134232 (2024).","journal-title":"Cancer Res."},{"key":"905_CR102","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez, C. X. et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 10, 232\u2013253 (2020).","journal-title":"Cancer Discov."},{"key":"905_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202415196","volume":"12","author":"M Tao","year":"2025","unstructured":"Tao, M. et al. Transcriptome landscape of cancer-associated fibroblasts in human PDAC. Adv. Sci. 12, e2415196 (2025).","journal-title":"Adv. Sci."},{"key":"905_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40895-6","volume":"14","author":"K Oh","year":"2023","unstructured":"Oh, K. et al. Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype. Nat. Commun. 14, 5226 (2023).","journal-title":"Nat. Commun."},{"key":"905_CR105","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang, H. et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell 40, 656\u2013673.e7 (2022).","journal-title":"Cancer Cell"},{"key":"905_CR106","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-3252","author":"J Cumming","year":"2025","unstructured":"Cumming, J. et al. Dissecting FAP+ cell diversity in pancreatic cancer uncovers an interferon-response subtype of cancer-associated fibroblasts with tumor-restraining properties. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-3252 (2025).","journal-title":"Cancer Res."},{"key":"905_CR107","doi-asserted-by":"publisher","first-page":"101248","DOI":"10.1016\/j.xcrm.2023.101248","volume":"4","author":"S Mascharak","year":"2023","unstructured":"Mascharak, S. et al. Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma. Cell Rep. Med. 4, 101248 (2023).","journal-title":"Cell Rep. Med."},{"key":"905_CR108","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abb7066","author":"C Perez-Shibayama","year":"2020","unstructured":"Perez-Shibayama, C. et al. Type I interferon signaling in fibroblastic reticular cells prevents exhaustive activation of antiviral CD8+ T cells. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abb7066 (2020).","journal-title":"Sci. Immunol."},{"key":"905_CR109","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1084\/jem.20092642","volume":"207","author":"AL Fletcher","year":"2010","unstructured":"Fletcher, A. L. et al. Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. J. Exp. Med. 207, 689\u2013697 (2010).","journal-title":"J. Exp. Med."},{"key":"905_CR110","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi, G. et al. IL1-induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 9, 282\u2013301 (2019).","journal-title":"Cancer Discov."},{"key":"905_CR111","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D Ohlund","year":"2017","unstructured":"Ohlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579\u2013596 (2017). This study was the first to describe spatially defined populations of myCAFs and putative iCAFs in PDAC, observations subsequently validated in numerous single-cell genomic studies of mouse and human PDAC.","journal-title":"J. Exp. Med."},{"key":"905_CR112","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41586-025-08927-x","volume":"642","author":"G Pei","year":"2025","unstructured":"Pei, G. et al. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Nature 642, 212\u2013221 (2025).","journal-title":"Nature"},{"key":"905_CR113","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1158\/1078-0432.CCR-24-2183","volume":"31","author":"IM Loveless","year":"2025","unstructured":"Loveless, I. M. et al. Human pancreatic cancer single-cell atlas reveals association of CXCL10+\u2009fibroblasts and basal subtype tumor cells. Clin. Cancer Res. 31, 756\u2013772 (2025).","journal-title":"Clin. Cancer Res."},{"key":"905_CR114","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ccell.2023.12.002","volume":"42","author":"G Mucciolo","year":"2024","unstructured":"Mucciolo, G. et al. EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. Cancer Cell 42, 101\u2013118.e1 (2024).","journal-title":"Cancer Cell"},{"key":"905_CR115","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1158\/2159-8290.CD-20-1484","volume":"12","author":"KM McAndrews","year":"2022","unstructured":"McAndrews, K. M. et al. Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer. Cancer Discov. 12, 1580\u20131597 (2022).","journal-title":"Cancer Discov."},{"key":"905_CR116","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC Ozdemir","year":"2014","unstructured":"Ozdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719\u2013734 (2014).","journal-title":"Cancer Cell"},{"key":"905_CR117","doi-asserted-by":"publisher","first-page":"103315","DOI":"10.1016\/j.ebiom.2021.103315","volume":"66","author":"K Chen","year":"2021","unstructured":"Chen, K. et al. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression. eBioMedicine 66, 103315 (2021).","journal-title":"eBioMedicine"},{"key":"905_CR118","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1158\/0008-5472.CAN-22-2316","volume":"83","author":"S Schworer","year":"2023","unstructured":"Schworer, S. et al. Hypoxia potentiates the inflammatory fibroblast phenotype promoted by pancreatic cancer cell-derived cytokines. Cancer Res. 83, 1596\u20131610 (2023).","journal-title":"Cancer Res."},{"key":"905_CR119","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-19-0454","volume":"79","author":"Y Mizutani","year":"2019","unstructured":"Mizutani, Y. et al. Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Res. 79, 5367\u20135381 (2019).","journal-title":"Cancer Res."},{"key":"905_CR120","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/SLA.0000000000006416","volume":"280","author":"JJ Lee","year":"2024","unstructured":"Lee, J. J. et al. Tumor-intrinsic and cancer-associated fibroblast subtypes independently predict outcomes in pancreatic cancer. Ann. Surg. 280, 659\u2013666 (2024).","journal-title":"Ann. Surg."},{"key":"905_CR121","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jcmgh.2020.05.004","volume":"10","author":"PE Garcia","year":"2020","unstructured":"Garcia, P. E. et al. Differential contribution of pancreatic fibroblast subsets to the pancreatic cancer stroma. Cell. Mol. Gastroenterol. Hepatol. 10, 581\u2013599 (2020). This study was the first to identify transcriptionally and spatially distinct populations of tissue-resident fibroblasts in healthy pancreas and to lineage-trace these cells to define their contributions to the pancreatic tumour stroma.","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"905_CR122","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12876-015-0340-0","volume":"15","author":"T Kawase","year":"2015","unstructured":"Kawase, T. et al. Fibroblast activation protein-alpha-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma. BMC Gastroenterol. 15, 109 (2015).","journal-title":"BMC Gastroenterol."},{"key":"905_CR123","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1136\/gutjnl-2022-329371","volume":"72","author":"E Karamitopoulou","year":"2023","unstructured":"Karamitopoulou, E. et al. Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. Gut 72, 1523\u20131533 (2023).","journal-title":"Gut"},{"key":"905_CR124","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-20-0775","volume":"11","author":"R Francescone","year":"2021","unstructured":"Francescone, R. et al. Netrin G1 promotes pancreatic tumorigenesis through cancer-associated fibroblast-driven nutritional support and immunosuppression. Cancer Discov. 11, 446\u2013479 (2021).","journal-title":"Cancer Discov."},{"key":"905_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50441-7","volume":"15","author":"B Assouline","year":"2024","unstructured":"Assouline, B. et al. Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice. Nat. Commun. 15, 6162 (2024).","journal-title":"Nat. Commun."},{"key":"905_CR126","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1158\/2159-8290.CD-21-0601","volume":"12","author":"EJ Helms","year":"2022","unstructured":"Helms, E. J. et al. Mesenchymal lineage heterogeneity underlies nonredundant functions of pancreatic cancer-associated fibroblasts. Cancer Discov. 12, 484\u2013501 (2022).","journal-title":"Cancer Discov."},{"key":"905_CR127","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146987","author":"S Bhattacharjee","year":"2021","unstructured":"Bhattacharjee, S. et al. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI146987 (2021).","journal-title":"J. Clin. Invest."},{"key":"905_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34464-6","volume":"14","author":"L Han","year":"2023","unstructured":"Han, L. et al. The splanchnic mesenchyme is the tissue of origin for pancreatic fibroblasts during homeostasis and tumorigenesis. Nat. Commun. 14, 1 (2023).","journal-title":"Nat. Commun."},{"key":"905_CR129","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.7150\/jca.24415","volume":"9","author":"K Saito","year":"2018","unstructured":"Saito, K. et al. Stromal mesenchymal stem cells facilitate pancreatic cancer progression by regulating specific secretory molecules through mutual cellular interaction. J. Cancer 9, 2916\u20132929 (2018).","journal-title":"J. Cancer"},{"key":"905_CR130","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/ijc.31775","volume":"144","author":"T Okumura","year":"2019","unstructured":"Okumura, T. et al. Adipose tissue-derived stromal cells are sources of cancer-associated fibroblasts and enhance tumor progression by dense collagen matrix. Int. J. Cancer 144, 1401\u20131413 (2019).","journal-title":"Int. J. Cancer"},{"key":"905_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84058-3","volume":"11","author":"Y Miyazaki","year":"2021","unstructured":"Miyazaki, Y. et al. Adipose-derived mesenchymal stem cells differentiate into heterogeneous cancer-associated fibroblasts in a stroma-rich xenograft model. Sci. Rep. 11, 4690 (2021).","journal-title":"Sci. Rep."},{"key":"905_CR132","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/2767-9764.CRC-24-0298","volume":"5","author":"J Rupert","year":"2025","unstructured":"Rupert, J. et al. Depletion of adipose stroma-like cancer-associated fibroblasts potentiates pancreatic cancer immunotherapy. Cancer Res. Commun. 5, 5\u201312 (2025).","journal-title":"Cancer Res. Commun."},{"key":"905_CR133","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.canlet.2021.04.013","volume":"512","author":"C Iwamoto","year":"2021","unstructured":"Iwamoto, C. et al. Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression. Cancer Lett. 512, 15\u201327 (2021).","journal-title":"Cancer Lett."},{"key":"905_CR134","doi-asserted-by":"publisher","first-page":"10123","DOI":"10.1158\/0008-5472.CAN-07-3127","volume":"67","author":"EM Zeisberg","year":"2007","unstructured":"Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M. & Kalluri, R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 67, 10123\u201310128 (2007).","journal-title":"Cancer Res."},{"key":"905_CR135","doi-asserted-by":"publisher","first-page":"E5618","DOI":"10.1073\/pnas.1608384113","volume":"113","author":"K Hosaka","year":"2016","unstructured":"Hosaka, K. et al. Pericyte-fibroblast transition promotes tumor growth and metastasis. Proc. Natl Acad. Sci. USA 113, E5618\u2013E5627 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"905_CR136","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-07-2477","volume":"68","author":"A Vonlaufen","year":"2008","unstructured":"Vonlaufen, A. et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 68, 2085\u20132093 (2008).","journal-title":"Cancer Res."},{"key":"905_CR137","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.cell.2016.03.029","volume":"165","author":"CJ Tape","year":"2016","unstructured":"Tape, C. J. et al. Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation. Cell 165, 910\u2013920 (2016).","journal-title":"Cell"},{"key":"905_CR138","doi-asserted-by":"publisher","first-page":"pgad405","DOI":"10.1093\/pnasnexus\/pgad405","volume":"2","author":"P Gamradt","year":"2023","unstructured":"Gamradt, P. et al. Stiffness-induced cancer-associated fibroblasts are responsible for immunosuppression in a platelet-derived growth factor ligand-dependent manner. PNAS Nexus 2, pgad405 (2023).","journal-title":"PNAS Nexus"},{"key":"905_CR139","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1158\/1078-0432.CCR-08-0291","volume":"14","author":"JM Bailey","year":"2008","unstructured":"Bailey, J. M. et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 14, 5995\u20136004 (2008).","journal-title":"Clin. Cancer Res."},{"key":"905_CR140","first-page":"550","volume":"61","author":"M Lohr","year":"2001","unstructured":"Lohr, M. et al. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 61, 550\u2013555 (2001).","journal-title":"Cancer Res."},{"key":"905_CR141","doi-asserted-by":"publisher","first-page":"9405","DOI":"10.1096\/fj.201902990R","volume":"34","author":"M Awaji","year":"2020","unstructured":"Awaji, M. et al. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. FASEB J. 34, 9405\u20139418 (2020).","journal-title":"FASEB J."},{"key":"905_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34081-3","volume":"13","author":"L Shaashua","year":"2022","unstructured":"Shaashua, L. et al. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling. Nat. Commun. 13, 6513 (2022).","journal-title":"Nat. Commun."},{"key":"905_CR143","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1158\/0008-5472.CAN-07-5714","volume":"68","author":"RF Hwang","year":"2008","unstructured":"Hwang, R. F. et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68, 918\u2013926 (2008).","journal-title":"Cancer Res."},{"key":"905_CR144","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2019.05.012","volume":"178","author":"M Ligorio","year":"2019","unstructured":"Ligorio, M. et al. Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer. Cell 178, 160\u2013175.e7 (2019).","journal-title":"Cell"},{"key":"905_CR145","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1158\/2159-8290.CD-18-1212","volume":"9","author":"FR Auciello","year":"2019","unstructured":"Auciello, F. R. et al. A stromal lysolipid-autotaxin signaling axis promotes pancreatic tumor progression. Cancer Discov. 9, 617\u2013627 (2019).","journal-title":"Cancer Discov."},{"key":"905_CR146","doi-asserted-by":"publisher","first-page":"114972","DOI":"10.1016\/j.celrep.2024.114972","volume":"43","author":"X Han","year":"2024","unstructured":"Han, X. et al. Cancer-associated fibroblasts maintain critical pancreatic cancer cell lipid homeostasis in the tumor microenvironment. Cell Rep. 43, 114972 (2024).","journal-title":"Cell Rep."},{"key":"905_CR147","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature19084","volume":"536","author":"CM Sousa","year":"2016","unstructured":"Sousa, C. M. et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 536, 479\u2013483 (2016).","journal-title":"Nature"},{"key":"905_CR148","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0119","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Macropinocytosis in cancer-associated fibroblasts is dependent on CaMKK2\/ARHGEF2 signaling and functions to support tumor and stromal cell fitness. Cancer Discov. 11, 1808\u20131825 (2021).","journal-title":"Cancer Discov."},{"key":"905_CR149","doi-asserted-by":"publisher","first-page":"78396","DOI":"10.18632\/oncotarget.11893","volume":"7","author":"ES Knudsen","year":"2016","unstructured":"Knudsen, E. S., Balaji, U., Freinkman, E., McCue, P. & Witkiewicz, A. K. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. Oncotarget 7, 78396\u201378411 (2016).","journal-title":"Oncotarget"},{"key":"905_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57769-6","volume":"14","author":"P Zhang","year":"2024","unstructured":"Zhang, P. et al. NNT-AS1 in CAFs-derived exosomes promotes progression and glucose metabolism through miR-889-3p\/HIF-1alpha in pancreatic adenocarcinoma. Sci. Rep. 14, 6979 (2024).","journal-title":"Sci. Rep."},{"key":"905_CR151","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1158\/2767-9764.CRC-21-0147","volume":"2","author":"KS Raghavan","year":"2022","unstructured":"Raghavan, K. S. et al. NetrinG1+ cancer-associated fibroblasts generate unique extracellular vesicles that support the survival of pancreatic cancer cells under nutritional stress. Cancer Res. Commun. 2, 1017\u20131036 (2022).","journal-title":"Cancer Res. Commun."},{"key":"905_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03168-4","volume":"11","author":"K Kesh","year":"2020","unstructured":"Kesh, K. et al. Stroma secreted IL6 selects for \u2018stem-like\u2019 population and alters pancreatic tumor microenvironment by reprogramming metabolic pathways. Cell Death Dis. 11, 967 (2020).","journal-title":"Cell Death Dis."},{"key":"905_CR153","doi-asserted-by":"publisher","first-page":"65982","DOI":"10.18632\/oncotarget.11786","volume":"7","author":"NS Nagathihalli","year":"2016","unstructured":"Nagathihalli, N. S. et al. Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells. Oncotarget 7, 65982\u201365992 (2016).","journal-title":"Oncotarget"},{"key":"905_CR154","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41586-019-1004-y","volume":"567","author":"JW Lee","year":"2019","unstructured":"Lee, J. W. et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 567, 249\u2013252 (2019).","journal-title":"Nature"},{"key":"905_CR155","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/cam4.993","volume":"6","author":"A Zhang","year":"2017","unstructured":"Zhang, A. et al. Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. Cancer Med. 6, 463\u2013470 (2017).","journal-title":"Cancer Med."},{"key":"905_CR156","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1053\/j.gastro.2013.07.025","volume":"145","author":"A Ene-Obong","year":"2013","unstructured":"Ene-Obong, A. et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology 145, 1121\u20131132 (2013).","journal-title":"Gastroenterology"},{"key":"905_CR157","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim, A. D. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735\u2013747 (2014).","journal-title":"Cancer Cell"},{"key":"905_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62416-x","volume":"10","author":"TM Pausch","year":"2020","unstructured":"Pausch, T. M. et al. Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes. Sci. Rep. 10, 5420 (2020).","journal-title":"Sci. Rep."},{"key":"905_CR159","doi-asserted-by":"publisher","first-page":"19609","DOI":"10.1073\/pnas.1908626116","volume":"116","author":"C Tian","year":"2019","unstructured":"Tian, C. et al. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc. Natl Acad. Sci. USA 116, 19609\u201319618 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"905_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.54","volume":"6","author":"AJ Rice","year":"2017","unstructured":"Rice, A. J. et al. Matrix stiffness induces epithelial\u2013mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis 6, e352 (2017).","journal-title":"Oncogenesis"},{"key":"905_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-154","volume":"13","author":"D Ohlund","year":"2013","unstructured":"Ohlund, D., Franklin, O., Lundberg, E., Lundin, C. & Sund, M. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. BMC Cancer 13, 154 (2013).","journal-title":"BMC Cancer"},{"key":"905_CR162","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.canlet.2014.10.020","volume":"356","author":"S Berchtold","year":"2015","unstructured":"Berchtold, S. et al. Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Cancer Lett. 356, 721\u2013732 (2015).","journal-title":"Cancer Lett."},{"key":"905_CR163","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.matbio.2022.11.002","volume":"114","author":"B Yan","year":"2022","unstructured":"Yan, B. et al. Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma. Matrix Biol. 114, 84\u2013107 (2022).","journal-title":"Matrix Biol."},{"key":"905_CR164","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021684","volume":"6","author":"I Paron","year":"2011","unstructured":"Paron, I. et al. Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. PLoS ONE 6, e21684 (2011).","journal-title":"PLoS ONE"},{"key":"905_CR165","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1083\/jcb.201704053","volume":"216","author":"B Erdogan","year":"2017","unstructured":"Erdogan, B. et al. Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. J. Cell Biol. 216, 3799\u20133816 (2017).","journal-title":"J. Cell Biol."},{"key":"905_CR166","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ccell.2021.02.007","volume":"39","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Type I collagen deletion in \u03b1SMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell 39, 548\u2013565.e6 (2021).","journal-title":"Cancer Cell"},{"key":"905_CR167","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.ccell.2022.06.011","volume":"40","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Oncogenic collagen I homotrimers from cancer cells bind to \u03b13\u03b21 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell 40, 818\u2013834.e9 (2022).","journal-title":"Cancer Cell"},{"key":"905_CR168","doi-asserted-by":"publisher","first-page":"10495","DOI":"10.1074\/jbc.M110.195628","volume":"286","author":"MA Shields","year":"2011","unstructured":"Shields, M. A., Dangi-Garimella, S., Krantz, S. B., Bentrem, D. J. & Munshi, H. G. Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J. Biol. Chem. 286, 10495\u201310504 (2011).","journal-title":"J. Biol. Chem."},{"key":"905_CR169","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52\u201367 (2010).","journal-title":"Cell"},{"key":"905_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12930-y","volume":"10","author":"R Ferrari","year":"2019","unstructured":"Ferrari, R. et al. MT1\u2013MMP directs force-producing proteolytic contacts that drive tumor cell invasion. Nat. Commun. 10, 4886 (2019).","journal-title":"Nat. Commun."},{"key":"905_CR171","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41586-022-05169-z","volume":"610","author":"H Su","year":"2022","unstructured":"Su, H. et al. Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome. Nature 610, 366\u2013372 (2022).","journal-title":"Nature"},{"key":"905_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16031","volume":"8","author":"O Olivares","year":"2017","unstructured":"Olivares, O. et al. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat. Commun. 8, 16031 (2017).","journal-title":"Nat. Commun."},{"key":"905_CR173","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1158\/1541-7786.MCR-13-0557-T","volume":"12","author":"C Mehner","year":"2014","unstructured":"Mehner, C. et al. Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma. Mol. Cancer Res. 12, 1430\u20131439 (2014).","journal-title":"Mol. Cancer Res."},{"key":"905_CR174","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/cas.16418","volume":"116","author":"Z Wang","year":"2025","unstructured":"Wang, Z. et al. Cancer-associated fibroblast-derived MMP11 promotes tumor progression in pancreatic cancer. Cancer Sci. 116, 643\u2013655 (2025).","journal-title":"Cancer Sci."},{"key":"905_CR175","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/1541-7786.MCR-16-0180","volume":"14","author":"B Grunwald","year":"2016","unstructured":"Grunwald, B. et al. Systemic ablation of MMP-9 triggers invasive growth and metastasis of pancreatic cancer via deregulation of IL6 expression in the bone marrow. Mol. Cancer Res. 14, 1147\u20131158 (2016). This study defined the existence of recurrent sub-TMEs in human PDAC tissues and showed associations between these spatial features and patient outcomes.","journal-title":"Mol. Cancer Res."},{"key":"905_CR176","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm.4123","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang, H. et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 22, 851\u2013860 (2016).","journal-title":"Nat. Med."},{"key":"905_CR177","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1158\/1078-0432.CCR-13-2972","volume":"20","author":"N Hartmann","year":"2014","unstructured":"Hartmann, N. et al. Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer. Clin. Cancer Res. 20, 3422\u20133433 (2014).","journal-title":"Clin. Cancer Res."},{"key":"905_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10671-w","volume":"7","author":"MD Nieskoski","year":"2017","unstructured":"Nieskoski, M. D. et al. Collagen complexity spatially defines microregions of total tissue pressure in pancreatic cancer. Sci. Rep. 7, 10093 (2017).","journal-title":"Sci. Rep."},{"key":"905_CR179","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","volume":"62","author":"MA Jacobetz","year":"2013","unstructured":"Jacobetz, M. A. et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62, 112\u2013120 (2013).","journal-title":"Gut"},{"key":"905_CR180","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418\u2013429 (2012).","journal-title":"Cancer Cell"},{"key":"905_CR181","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.1171362","volume":"324","author":"KP Olive","year":"2009","unstructured":"Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457\u20131461 (2009).","journal-title":"Science"},{"key":"905_CR182","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/gutjnl-2016-311954","volume":"67","author":"E Hessmann","year":"2018","unstructured":"Hessmann, E. et al. Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut 67, 497\u2013507 (2018).","journal-title":"Gut"},{"key":"905_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07431-4","volume":"16","author":"R He","year":"2025","unstructured":"He, R. et al. Glycolysis reprogramming in CAFs promotes oxaliplatin resistance in pancreatic cancer through circABCC4 mediated PKM2 nuclear translocation. Cell Death Dis. 16, 126 (2025).","journal-title":"Cell Death Dis."},{"key":"905_CR184","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0360-3016(00)00803-8","volume":"48","author":"AC Koong","year":"2000","unstructured":"Koong, A. C. et al. Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 48, 919\u2013922 (2000).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"905_CR185","doi-asserted-by":"publisher","DOI":"10.1172\/JCI136655","author":"BM Kahn","year":"2021","unstructured":"Kahn, B. M. et al. The vascular landscape of human cancer. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI136655 (2021).","journal-title":"J. Clin. Invest."},{"key":"905_CR186","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3389\/fbioe.2019.00397","volume":"7","author":"M Zaidi","year":"2019","unstructured":"Zaidi, M., Fu, F., Cojocari, D., McKee, T. D. & Wouters, B. G. Quantitative visualization of hypoxia and proliferation gradients within histological tissue sections. Front. Bioeng. Biotechnol. 7, 397 (2019).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"905_CR187","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.3390\/cancers2042138","volume":"2","author":"S Vasseur","year":"2010","unstructured":"Vasseur, S., Tomasini, R., Tournaire, R. & Iovanna, J. L. Hypoxia induced tumor metabolic switch contributes to pancreatic cancer aggressiveness. Cancers 2, 2138\u20132152 (2010).","journal-title":"Cancers"},{"key":"905_CR188","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1158\/0008-5472.CAN-22-2945","volume":"84","author":"BA Brown","year":"2024","unstructured":"Brown, B. A. et al. A histone methylation-MAPK signaling axis drives durable epithelial\u2013mesenchymal transition in hypoxic pancreatic cancer. Cancer Res. 84, 1764\u20131780 (2024).","journal-title":"Cancer Res."},{"key":"905_CR189","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1158\/2159-8290.CD-15-0822","volume":"6","author":"KE Lee","year":"2016","unstructured":"Lee, K. E. et al. Hif1a deletion reveals pro-neoplastic function of b cells in pancreatic neoplasia. Cancer Discov. 6, 256\u2013269 (2016).","journal-title":"Cancer Discov."},{"key":"905_CR190","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1158\/0008-5472.CAN-22-0431","volume":"82","author":"Y Sela","year":"2022","unstructured":"Sela, Y. et al. Bcl-xL enforces a slow-cycling state necessary for survival in the nutrient-deprived microenvironment of pancreatic cancer. Cancer Res. 82, 1890\u20131908 (2022).","journal-title":"Cancer Res."},{"key":"905_CR191","doi-asserted-by":"publisher","first-page":"8882","DOI":"10.1073\/pnas.1307237110","volume":"110","author":"JJ Kamphorst","year":"2013","unstructured":"Kamphorst, J. J. et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl Acad. Sci. USA 110, 8882\u20138887 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"905_CR192","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s42255-022-00583-z","volume":"4","author":"J Garcia-Bermudez","year":"2022","unstructured":"Garcia-Bermudez, J. et al. Adaptive stimulation of macropinocytosis overcomes aspartate limitation in cancer cells under hypoxia. Nat. Metab. 4, 724\u2013738 (2022).","journal-title":"Nat. Metab."},{"key":"905_CR193","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1158\/0008-5472.CAN-23-2352","volume":"84","author":"JH Sussman","year":"2024","unstructured":"Sussman, J. H. et al. Multiplexed imaging mass cytometry analysis characterizes the vascular niche in pancreatic cancer. Cancer Res. 84, 2364\u20132376 (2024). This study provided a high-resolution characterization of the spatial features of the vascular niche in human PDAC.","journal-title":"Cancer Res."},{"key":"905_CR194","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2159-8290.CD-23-0240","volume":"14","author":"MC Hasselluhn","year":"2024","unstructured":"Hasselluhn, M. C. et al. Tumor explants elucidate a cascade of paracrine SHH, WNT, and VEGF signals driving pancreatic cancer angiosuppression. Cancer Discov. 14, 348\u2013361 (2024).","journal-title":"Cancer Discov."},{"key":"905_CR195","doi-asserted-by":"publisher","first-page":"114236","DOI":"10.1016\/j.celrep.2024.114236","volume":"43","author":"C Lior","year":"2024","unstructured":"Lior, C. et al. Mapping the tumor stress network reveals dynamic shifts in the stromal oxidative stress response. Cell Rep. 43, 114236 (2024).","journal-title":"Cell Rep."},{"key":"905_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102448","author":"V Natarajan","year":"2022","unstructured":"Natarajan, V. et al. Acquired \u03b1SMA expression in pericytes coincides with aberrant vascular structure and function in pancreatic ductal adenocarcinoma. Cancers https:\/\/doi.org\/10.3390\/cancers14102448 (2022).","journal-title":"Cancers"},{"key":"905_CR197","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202256524","volume":"24","author":"Z Wu","year":"2023","unstructured":"Wu, Z. et al. Pericyte stem cells induce Ly6G+ cell accumulation and immunotherapy resistance in pancreatic cancer. EMBO Rep. 24, e56524 (2023).","journal-title":"EMBO Rep."},{"key":"905_CR198","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1073\/pnas.1018892108","volume":"108","author":"B Diop-Frimpong","year":"2011","unstructured":"Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y. & Jain, R. K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl Acad. Sci. USA 108, 2909\u20132914 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"905_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3516","volume":"4","author":"VP Chauhan","year":"2013","unstructured":"Chauhan, V. P. et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4, 2516 (2013).","journal-title":"Nat. Commun."},{"key":"905_CR200","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cell.2020.03.008","volume":"181","author":"M Ruscetti","year":"2020","unstructured":"Ruscetti, M. et al. Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer. Cell 181, 424\u2013441.e1 (2020).","journal-title":"Cell"},{"key":"905_CR201","doi-asserted-by":"publisher","first-page":"eadn0904","DOI":"10.1126\/scitranslmed.adn0904","volume":"16","author":"Z Lu","year":"2024","unstructured":"Lu, Z. et al. Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies. Sci. Transl. Med. 16, eadn0904 (2024).","journal-title":"Sci. Transl. Med."},{"key":"905_CR202","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1161\/CIRCULATIONAHA.118.036344","volume":"139","author":"KJ Bubb","year":"2019","unstructured":"Bubb, K. J. et al. Endothelial C-type natriuretic peptide is a critical regulator of angiogenesis and vascular remodeling. Circulation 139, 1612\u20131628 (2019).","journal-title":"Circulation"},{"key":"905_CR203","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/path.5260","volume":"248","author":"RH Hruban","year":"2019","unstructured":"Hruban, R. H. et al. Why is pancreatic cancer so deadly? The pathologist\u2019s view. J. Pathol. 248, 131\u2013141 (2019).","journal-title":"J. Pathol."},{"key":"905_CR204","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.pan.2020.08.015","volume":"20","author":"SJ Lee","year":"2020","unstructured":"Lee, S. J. et al. Comprehensive histological evaluation with clinical analysis of venous invasion in pancreatic ductal adenocarcinoma: from histology to clinical implications. Pancreatology 20, 1486\u20131494 (2020).","journal-title":"Pancreatology"},{"key":"905_CR205","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ebiom.2019.08.044","volume":"47","author":"CN Shen","year":"2019","unstructured":"Shen, C. N. et al. Lymphatic vessel remodeling and invasion in pancreatic cancer progression. eBioMedicine 47, 98\u2013113 (2019).","journal-title":"eBioMedicine"},{"key":"905_CR206","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157644","author":"Y Luo","year":"2022","unstructured":"Luo, Y. et al. KRAS mutant-driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI157644 (2022).","journal-title":"J. Clin. Invest."},{"key":"905_CR207","doi-asserted-by":"publisher","first-page":"eaav6789","DOI":"10.1126\/sciadv.aav6789","volume":"5","author":"DT Nguyen","year":"2019","unstructured":"Nguyen, D. T. et al. A biomimetic pancreatic cancer on-chip reveals endothelial ablation via ALK7 signaling. Sci. Adv. 5, eaav6789 (2019).","journal-title":"Sci. Adv."},{"key":"905_CR208","doi-asserted-by":"publisher","first-page":"7390","DOI":"10.1038\/s41598-021-86831-w","volume":"11","author":"A Ferdoushi","year":"2021","unstructured":"Ferdoushi, A. et al. Tumor innervation and clinical outcome in pancreatic cancer. Sci. Rep. 11, 7390 (2021).","journal-title":"Sci. Rep."},{"key":"905_CR209","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0000000000004464","volume":"276","author":"S Crippa","year":"2022","unstructured":"Crippa, S. et al. Implications of perineural invasion on disease recurrence and survival after pancreatectomy for pancreatic head ductal adenocarcinoma. Ann. Surg. 276, 378\u2013385 (2022).","journal-title":"Ann. Surg."},{"key":"905_CR210","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.pan.2025.04.010","volume":"25","author":"M Faghih","year":"2025","unstructured":"Faghih, M. et al. Pancreatic adenocarcinoma patients with pain have abnormal central pain processing. Pancreatology 25, 426\u2013432 (2025).","journal-title":"Pancreatology"},{"key":"905_CR211","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-025-08735-3","volume":"640","author":"V Thiel","year":"2025","unstructured":"Thiel, V. et al. Characterization of single neurons reprogrammed by pancreatic cancer. Nature 640, 1042\u20131051 (2025). This study identified the ganglia which project neurons into the pancreas and PDAC of mice and transcriptionally characterized these innervating neurons for the first time.","journal-title":"Nature"},{"key":"905_CR212","doi-asserted-by":"publisher","DOI":"10.3390\/cells11020280","author":"L Bizzozero","year":"2022","unstructured":"Bizzozero, L. et al. Tumoral neuroligin 1 promotes cancer\u2013nerve interactions and synergizes with the glial cell line-derived neurotrophic factor. Cells https:\/\/doi.org\/10.3390\/cells11020280 (2022).","journal-title":"Cells"},{"key":"905_CR213","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/SLA.0b013e3181d974d4","volume":"251","author":"GO Ceyhan","year":"2010","unstructured":"Ceyhan, G. O. et al. Nerve growth factor and artemin are paracrine mediators of pancreatic neuropathy in pancreatic adenocarcinoma. Ann. Surg. 251, 923\u2013931 (2010).","journal-title":"Ann. Surg."},{"key":"905_CR214","first-page":"3417","volume":"13","author":"Y-H Hung","year":"2023","unstructured":"Hung, Y.-H. et al. Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination. Am. J. Cancer Res. 13, 3417\u20133432 (2023).","journal-title":"Am. J. Cancer Res."},{"key":"905_CR215","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1111\/jcmm.15265","volume":"24","author":"J Jiang","year":"2020","unstructured":"Jiang, J., Bai, J., Qin, T., Wang, Z. & Han, L. NGF from pancreatic stellate cells induces pancreatic cancer proliferation and invasion by PI3K\/AKT\/GSK signal pathway. J. Cell. Mol. Med. 24, 5901\u20135910 (2020).","journal-title":"J. Cell. Mol. Med."},{"key":"905_CR216","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1053\/j.gastro.2019.05.065","volume":"157","author":"NR Jurcak","year":"2019","unstructured":"Jurcak, N. R. et al. Axon guidance molecules promote perineural invasion and metastasis of orthotopic pancreatic tumors in mice. Gastroenterology 157, 838\u2013850.e836 (2019).","journal-title":"Gastroenterology"},{"key":"905_CR217","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1158\/2159-8290.CD-18-0046","volume":"8","author":"BW Renz","year":"2018","unstructured":"Renz, B. W. et al. Cholinergic signaling via muscarinic receptors directly and indirectly suppresses pancreatic tumorigenesis and cancer stemness. Cancer Discov. 8, 1458\u20131473 (2018).","journal-title":"Cancer Discov."},{"key":"905_CR218","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1073\/pnas.1512603113","volume":"113","author":"JL Saloman","year":"2016","unstructured":"Saloman, J. L. et al. Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of cancer. Proc. Natl Acad. Sci. USA 113, 3078\u20133083 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"905_CR219","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/0008-5472.CAN-13-2050","volume":"74","author":"RE Stopczynski","year":"2014","unstructured":"Stopczynski, R. E. et al. Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma. Cancer Res. 74, 1718\u20131727 (2014).","journal-title":"Cancer Res."},{"key":"905_CR220","doi-asserted-by":"publisher","first-page":"5582811","DOI":"10.1155\/2022\/5582811","volume":"2022","author":"T Ji","year":"2022","unstructured":"Ji, T., Ma, K., Wu, H. & Cao, T. A substance P (SP)\/neurokinin-1 receptor axis promotes perineural invasion of pancreatic cancer and is affected by lncRNA LOC389641. J. Immunol. Res. 2022, 5582811 (2022).","journal-title":"J. Immunol. Res."},{"key":"905_CR221","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1158\/1541-7786.MCR-12-0609","volume":"11","author":"X Li","year":"2013","unstructured":"Li, X. et al. Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells. Mol. Cancer Res. 11, 294\u2013302 (2013).","journal-title":"Mol. Cancer Res."},{"key":"905_CR222","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1158\/0008-5472.CAN-16-0899","volume":"77","author":"S Sinha","year":"2017","unstructured":"Sinha, S. et al. PanIN neuroendocrine cells promote tumorigenesis via neuronal cross-talk. Cancer Res. 77, 1868\u20131879 (2017).","journal-title":"Cancer Res."},{"key":"905_CR223","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ccell.2017.11.007","volume":"33","author":"BW Renz","year":"2018","unstructured":"Renz, B. W. et al. \u03b22 Adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell 33, 75\u201390.e7 (2018). This study established a functional role for sympathetic nerves and catecholamine signalling in PDAC progression.","journal-title":"Cancer Cell"},{"key":"905_CR224","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/1535-7163.MCT-12-0809","volume":"12","author":"K Guo","year":"2013","unstructured":"Guo, K. et al. Interaction of the sympathetic nerve with pancreatic cancer cells promotes perineural invasion through the activation of STAT3 signaling. Mol. Cancer Ther. 12, 264\u2013273 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"905_CR225","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2016.01.026","volume":"373","author":"C Wan","year":"2016","unstructured":"Wan, C. et al. \u03b22-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression. Cancer Lett. 373, 67\u201376 (2016).","journal-title":"Cancer Lett."},{"key":"905_CR226","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10735-022-10076-8","volume":"53","author":"C Gong","year":"2022","unstructured":"Gong, C. et al. \u03b22-adrenergic receptor drives the metastasis and invasion of pancreatic ductal adenocarcinoma through activating Cdc42 signaling pathway. J. Mol. Histol. 53, 645\u2013655 (2022).","journal-title":"J. Mol. Histol."},{"key":"905_CR227","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/pon.1697","volume":"19","author":"KL Clark","year":"2010","unstructured":"Clark, K. L., Loscalzo, M., Trask, P. C., Zabora, J. & Philip, E. J. Psychological distress in patients with pancreatic cancer \u2014 an understudied group. Psycho-oncology 19, 1313\u20131320 (2010).","journal-title":"Psycho-oncology"},{"key":"905_CR228","doi-asserted-by":"publisher","unstructured":"Blair, A. B. et al. Nonselective \u03b2-adrenergic blockade impacts pancreatic cancer tumor biology, decreases perineural invasion and improves patient survival. Ann. Pancreatic Cancer https:\/\/doi.org\/10.21037\/apc-19-45 (2020).","DOI":"10.21037\/apc-19-45"},{"key":"905_CR229","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1158\/0008-5472.CAN-17-0108","volume":"77","author":"R Udumyan","year":"2017","unstructured":"Udumyan, R. et al. Beta-blocker drug use and survival among patients with pancreatic adenocarcinoma. Cancer Res. 77, 3700\u20133707 (2017).","journal-title":"Cancer Res."},{"key":"905_CR230","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/jhbp.1295","volume":"30","author":"T Ikeda","year":"2023","unstructured":"Ikeda, T. et al. Stress exacerbates pancreatic cancer both directly and indirectly by creating an immunosuppressive environment. J. Hepato-Biliary-Pancreatic Sci. 30, 935\u2013943 (2023).","journal-title":"J. Hepato-Biliary-Pancreatic Sci."},{"key":"905_CR231","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bbi.2014.02.019","volume":"40","author":"C Kim-Fuchs","year":"2014","unstructured":"Kim-Fuchs, C. et al. Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment. Brain Behav. Immun. 40, 40\u201347 (2014).","journal-title":"Brain Behav. Immun."},{"key":"905_CR232","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.pan.2016.03.005","volume":"16","author":"LI Partecke","year":"2016","unstructured":"Partecke, L. I. et al. Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade. Pancreatology 16, 423\u2013433 (2016).","journal-title":"Pancreatology"},{"key":"905_CR233","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41586-023-06568-6","volume":"622","author":"A-M Globig","year":"2023","unstructured":"Globig, A.-M. et al. The \u03b21-adrenergic receptor links sympathetic nerves to T\u2009cell exhaustion. Nature 622, 383\u2013392 (2023).","journal-title":"Nature"},{"key":"905_CR234","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1158\/0008-5472.CAN-19-2689","volume":"80","author":"M-W Yang","year":"2020","unstructured":"Yang, M.-W. et al. Perineural invasion reprograms the immune microenvironment through cholinergic signaling in pancreatic ductal adenocarcinoma. Cancer Res. 80, 1991\u20132003 (2020).","journal-title":"Cancer Res."},{"key":"905_CR235","doi-asserted-by":"publisher","first-page":"180","DOI":"10.21147\/j.issn.1000-9604.2016.02.05","volume":"28","author":"L Zhang","year":"2016","unstructured":"Zhang, L., Guo, L., Tao, M., Fu, W. & Xiu, D. Parasympathetic neurogenesis is strongly associated with tumor budding and correlates with an adverse prognosis in pancreatic ductal adenocarcinoma. Chin. J. Cancer Res. 28, 180\u2013186 (2016).","journal-title":"Chin. J. Cancer Res."},{"key":"905_CR236","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-025-01098-4","author":"K Wang","year":"2025","unstructured":"Wang, K. et al. Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells. Cell Res. https:\/\/doi.org\/10.1038\/s41422-025-01098-4 (2025).","journal-title":"Cell Res."},{"key":"905_CR237","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1158\/0008-5472.CAN-24-3173","volume":"85","author":"T Li","year":"2025","unstructured":"Li, T. et al. Cancer-associated fibroblasts foster a high-lactate microenvironment to drive perineural invasion in pancreatic cancer. Cancer Res 85, 2199\u20132217 (2025).","journal-title":"Cancer Res"},{"key":"905_CR238","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1158\/1541-7786.MCR-19-0726","volume":"18","author":"N Chernichenko","year":"2020","unstructured":"Chernichenko, N. et al. Cdc42 mediates cancer cell chemotaxis in perineural invasion. Mol. Cancer Res. 18, 913\u2013925 (2020).","journal-title":"Mol. Cancer Res."},{"key":"905_CR239","doi-asserted-by":"publisher","first-page":"E2008","DOI":"10.1073\/pnas.1402944111","volume":"111","author":"S He","year":"2014","unstructured":"He, S. et al. GFR\u03b11 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling. Proc. Natl Acad. Sci. USA 111, E2008\u2013E2017 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"905_CR240","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1158\/1541-7786.MCR-14-0303","volume":"13","author":"S He","year":"2015","unstructured":"He, S. et al. The chemokine (CCL2-CCR2) signaling axis mediates perineural invasion. Mol. Cancer Res.13, 380\u2013390 (2015).","journal-title":"Mol. Cancer Res."},{"key":"905_CR241","doi-asserted-by":"publisher","first-page":"106555","DOI":"10.1016\/j.phrs.2022.106555","volume":"187","author":"F Li","year":"2023","unstructured":"Li, F. et al. Glutamate from nerve cells promotes perineural invasion in pancreatic cancer by regulating tumor glycolysis through HK2 mRNA-m6A modification. Pharmacol. Res. 187, 106555 (2023).","journal-title":"Pharmacol. Res."},{"key":"905_CR242","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12032-025-02736-y","volume":"42","author":"Z Zhang","year":"2025","unstructured":"Zhang, Z. et al. TGFBI promotes EMT and perineural invasion of pancreatic cancer via PI3K\/AKT pathway. Med. Oncol. 42, 181 (2025).","journal-title":"Med. Oncol."},{"key":"905_CR243","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1158\/2159-8290.CD-21-1690","volume":"12","author":"S Deborde","year":"2022","unstructured":"Deborde, S. et al. Reprogrammed Schwann cells organize into dynamic tracks that promote pancreatic cancer invasion. Cancer Discov. 12, 2454\u20132473 (2022).","journal-title":"Cancer Discov."},{"key":"905_CR244","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2210735120","volume":"120","author":"AR Marcadis","year":"2023","unstructured":"Marcadis, A. R. et al. Rapid cancer cell perineural invasion utilizes amoeboid migration. Proc. Natl Acad. Sci. USA 120, e2210735120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"905_CR245","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.cell.2024.11.002","volume":"188","author":"SK Tetzlaff","year":"2025","unstructured":"Tetzlaff, S. K. et al. Characterizing and targeting glioblastoma neuron\u2013tumor networks with retrograde tracing. Cell 188, 390\u2013411.e6 (2025).","journal-title":"Cell"},{"key":"905_CR246","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.cell.2022.06.054","volume":"185","author":"V Venkataramani","year":"2022","unstructured":"Venkataramani, V. et al. Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell 185, 2899\u20132917.e31 (2022).","journal-title":"Cell"},{"key":"905_CR247","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.cell.2015.04.012","volume":"161","author":"HS Venkatesh","year":"2015","unstructured":"Venkatesh, H. S. et al. Neuronal activity promotes glioma growth through neuroligin-3 secretion. Cell 161, 803\u2013816 (2015).","journal-title":"Cell"},{"key":"905_CR248","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168\u20131178 (2015).","journal-title":"Nat. Genet."},{"key":"905_CR249","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 (2016).","journal-title":"Nature"},{"key":"905_CR250","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185\u2013203.e13 (2017).","journal-title":"Cancer Cell"},{"key":"905_CR251","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung, K. L. et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin. Cancer Res. 24, 1344\u20131354 (2018).","journal-title":"Clin. Cancer Res."},{"key":"905_CR252","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55330-7","volume":"16","author":"L Klein","year":"2025","unstructured":"Klein, L. et al. Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer. Nat. Commun. 16, 335 (2025).","journal-title":"Nat. Commun."},{"key":"905_CR253","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41588-022-01134-8","volume":"54","author":"WL Hwang","year":"2022","unstructured":"Hwang, W. L. et al. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Nat. Genet. 54, 1178\u20131191 (2022). This study was the first application of spatial transcriptomics to human PDAC and used spatial data together with single-nucleus RNA sequencing to identify a novel tumour cell state emerging after treatment and potentially associated with resistance.","journal-title":"Nat. Genet."},{"key":"905_CR254","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1038\/s41588-024-01890-9","volume":"56","author":"C Shiau","year":"2024","unstructured":"Shiau, C. et al. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Nat. Genet. 56, 2466\u20132478 (2024).","journal-title":"Nat. Genet."},{"key":"905_CR255","doi-asserted-by":"publisher","first-page":"100726","DOI":"10.1016\/j.modpat.2025.100726","volume":"38","author":"TN Alver","year":"2025","unstructured":"Alver, T. N. et al. Spatial transcriptomics reveals cancer and stromal cell heterogeneity between center and invasive front of pancreatic cancer. Mod. Pathol. 38, 100726 (2025).","journal-title":"Mod. Pathol."},{"key":"905_CR256","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.86125","author":"W Croft","year":"2023","unstructured":"Croft, W. et al. Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma. eLife https:\/\/doi.org\/10.7554\/eLife.86125 (2023).","journal-title":"eLife"},{"key":"905_CR257","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat3487","author":"L Zhou","year":"2018","unstructured":"Zhou, L. et al. Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aat3487 (2018).","journal-title":"Sci. Transl. Med."},{"key":"905_CR258","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00595-017-1559-x","volume":"48","author":"K Hirayama","year":"2018","unstructured":"Hirayama, K. et al. Expression of podoplanin in stromal fibroblasts plays a pivotal role in the prognosis of patients with pancreatic cancer. Surg. Today 48, 110\u2013118 (2018).","journal-title":"Surg. Today"},{"key":"905_CR259","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.ccell.2025.03.004","volume":"43","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics. Cancer Cell 43, 905\u2013924.e6 (2025).","journal-title":"Cancer Cell"},{"key":"905_CR260","doi-asserted-by":"publisher","first-page":"995715","DOI":"10.3389\/fimmu.2022.995715","volume":"13","author":"HM Aziz","year":"2022","unstructured":"Aziz, H. M. et al. Spatial genomics reveals a high number and specific location of B cells in the pancreatic ductal adenocarcinoma microenvironment of long-term survivors. Front. Immunol. 13, 995715 (2022).","journal-title":"Front. Immunol."},{"key":"905_CR261","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-86950-8","volume":"15","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Single-cell transcriptomics analysis reveals dynamic changes and prognostic signature in tumor microenvironment of PDAC. Sci. Rep. 15, 4025 (2025).","journal-title":"Sci. Rep."},{"key":"905_CR262","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.7150\/thno.73222","volume":"12","author":"S Han","year":"2022","unstructured":"Han, S. et al. Single-cell profiling of microenvironment components by spatial localization in pancreatic ductal adenocarcinoma. Theranostics 12, 4980\u20134992 (2022).","journal-title":"Theranostics"},{"key":"905_CR263","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nri3073","volume":"11","author":"PJ Murray","year":"2011","unstructured":"Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11, 723\u2013737 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"905_CR264","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1158\/0008-5472.CAN-12-0764","volume":"72","author":"O Cavel","year":"2012","unstructured":"Cavel, O. et al. Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor. Cancer Res. 72, 5733\u20135743 (2012).","journal-title":"Cancer Res."},{"key":"905_CR265","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1038\/onc.2016.483","volume":"36","author":"M Amit","year":"2017","unstructured":"Amit, M. et al. Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma. Oncogene 36, 3232\u20133239 (2017).","journal-title":"Oncogene"},{"key":"905_CR266","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41416-023-02539-w","volume":"130","author":"B Zhang","year":"2024","unstructured":"Zhang, B. et al. Tumour-associated macrophages and Schwann cells promote perineural invasion via paracrine loop in pancreatic ductal adenocarcinoma. Br. J. Cancer 130, 542\u2013554 (2024).","journal-title":"Br. J. Cancer"},{"key":"905_CR267","doi-asserted-by":"publisher","first-page":"18632","DOI":"10.1073\/pnas.1318415110","volume":"110","author":"T Stylianopoulos","year":"2013","unstructured":"Stylianopoulos, T. & Jain, R. K. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc. Natl Acad. Sci. USA 110, 18632\u201318637 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"905_CR268","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/gutjnl-2018-316451","volume":"68","author":"A Neesse","year":"2019","unstructured":"Neesse, A. et al. Stromal biology and therapy in pancreatic cancer: ready for clinical translation. Gut 68, 159\u2013171 (2019).","journal-title":"Gut"},{"key":"905_CR269","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan, Z. et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol. Cancer 22, 48 (2023).","journal-title":"Mol. Cancer"},{"key":"905_CR270","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/0008-5472.CAN-18-1334","volume":"79","author":"KY Elahi-Gedwillo","year":"2019","unstructured":"Elahi-Gedwillo, K. Y., Carlson, M., Zettervall, J. & Provenzano, P. P. Antifibrotic therapy disrupts stromal barriers and modulates the immune landscape in pancreatic ductal adenocarcinoma. Cancer Res. 79, 372\u2013386 (2019).","journal-title":"Cancer Res."},{"key":"905_CR271","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","volume":"36","author":"SR Hingorani","year":"2018","unstructured":"Hingorani, S. R. et al. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J. Clin. Oncol. 36, 359\u2013366 (2018).","journal-title":"J. Clin. Oncol."},{"key":"905_CR272","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2217\/fon-2017-0338","volume":"14","author":"GJ Doherty","year":"2018","unstructured":"Doherty, G. J., Tempero, M. & Corrie, P. G. HALO-109-301: a phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol. 14, 13\u201322 (2018).","journal-title":"Future Oncol."},{"key":"905_CR273","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1200\/JCO.18.01295","volume":"37","author":"RK Ramanathan","year":"2019","unstructured":"Ramanathan, R. K. et al. Phase IB\/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J. Clin. Oncol. 37, 1062\u20131069 (2019).","journal-title":"J. Clin. Oncol."},{"key":"905_CR274","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","volume":"38","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem, E. et al. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 38, 3185\u20133194 (2020).","journal-title":"J. Clin. Oncol."},{"key":"905_CR275","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/oncolo\/oyad022","volume":"28","author":"AH Ko","year":"2023","unstructured":"Ko, A. H. et al. Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer: MORPHEUS phase Ib\/II umbrella randomized study platform. Oncologist 28, 553-e472 (2023).","journal-title":"Oncologist"},{"key":"905_CR276","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150330","author":"A Ray","year":"2022","unstructured":"Ray, A. et al. Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.150330 (2022).","journal-title":"JCI Insight"},{"key":"905_CR277","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1158\/2159-8290.CD-22-0192","volume":"12","author":"VE Lander","year":"2022","unstructured":"Lander, V. E. et al. Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade. Cancer Discov. 12, 2774\u20132799 (2022).","journal-title":"Cancer Discov."},{"key":"905_CR278","doi-asserted-by":"publisher","first-page":"eado2402","DOI":"10.1126\/scitranslmed.ado2402","volume":"16","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. Sci. Transl. Med. 16, eado2402 (2024).","journal-title":"Sci. Transl. Med."},{"key":"905_CR279","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","volume":"28","author":"A Wang-Gillam","year":"2022","unstructured":"Wang-Gillam, A. et al. Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: a phase I dose escalation and expansion study. Clin. Cancer Res. 28, 5254\u20135262 (2022).","journal-title":"Clin. Cancer Res."},{"key":"905_CR280","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S2468-1253(22)00167-4","volume":"7","author":"A Dean","year":"2022","unstructured":"Dean, A. et al. Dual \u03b1V-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study. Lancet Gastroenterol. Hepatol. 7, 943\u2013951 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"905_CR281","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/oncolo\/oyad002","volume":"28","author":"K Perez","year":"2023","unstructured":"Perez, K. et al. Phase Ib and expansion study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with metastatic pancreatic cancer. Oncologist 28, 425\u2013432 (2023).","journal-title":"Oncologist"},{"key":"905_CR282","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1634\/theoncologist.2017-0024","volume":"22","author":"AB Benson III","year":"2017","unstructured":"Benson, A. B. III et al. A phase II randomized, double-blind, placebo-controlled study of simtuzumab or placebo in combination with gemcitabine for the first-line treatment of pancreatic adenocarcinoma. Oncologist 22, 241-e15 (2017).","journal-title":"Oncologist"},{"key":"905_CR283","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1053\/j.gastro.2011.06.047","volume":"141","author":"FE Froeling","year":"2011","unstructured":"Froeling, F. E. et al. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-beta-catenin signaling to slow tumor progression. Gastroenterology 141, 1486\u20131497 (2011).","journal-title":"Gastroenterology"},{"key":"905_CR284","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","volume":"159","author":"MH Sherman","year":"2014","unstructured":"Sherman, M. H. et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159, 80\u201393 (2014).","journal-title":"Cell"},{"key":"905_CR285","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae323","author":"V Chung","year":"2025","unstructured":"Chung, V. et al. Pembrolizumab\u2009\u00b1\u2009paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Oncologist https:\/\/doi.org\/10.1093\/oncolo\/oyae323 (2025).","journal-title":"Oncologist"},{"key":"905_CR286","doi-asserted-by":"publisher","first-page":"101881","DOI":"10.1016\/j.xcrm.2024.101881","volume":"6","author":"GP Nagaraju","year":"2025","unstructured":"Nagaraju, G. P. et al. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Cell Rep. Med. 6, 101881 (2025).","journal-title":"Cell Rep. Med."},{"key":"905_CR287","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18636-w","volume":"11","author":"HM Kocher","year":"2020","unstructured":"Kocher, H. M. et al. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat. Commun. 11, 4841 (2020).","journal-title":"Nat. Commun."},{"key":"905_CR288","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1078-0432.CCR-22-1630","volume":"29","author":"Y Boucher","year":"2023","unstructured":"Boucher, Y. et al. Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs, and FOXP3+\u2009cancer cells in locally advanced pancreatic cancer. Clin. Cancer Res. 29, 1605\u20131619 (2023).","journal-title":"Clin. Cancer Res."},{"key":"905_CR289","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","volume":"5","author":"JE Murphy","year":"2019","unstructured":"Murphy, J. E. et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. 5, 1020\u20131027 (2019).","journal-title":"JAMA Oncol."},{"key":"905_CR290","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007883","author":"M Callahan","year":"2024","unstructured":"Callahan, M. et al. Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032). J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2023-007883 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"905_CR291","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","volume":"5","author":"EM O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1431\u20131438 (2019).","journal-title":"JAMA Oncol."},{"key":"905_CR292","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-0099","volume":"26","author":"ZA Wainberg","year":"2020","unstructured":"Wainberg, Z. A. et al. Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. Clin. Cancer Res. 26, 4814\u20134822 (2020).","journal-title":"Clin. Cancer Res."},{"key":"905_CR293","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002068","author":"D Melisi","year":"2021","unstructured":"Melisi, D. et al. Safety and activity of the TGFbeta receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-002068 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"905_CR294","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padron","year":"2022","unstructured":"Padron, L. J. et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med. 28, 1167\u20131177 (2022).","journal-title":"Nat. Med."},{"key":"905_CR295","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","volume":"22","author":"MH O\u2019Hara","year":"2021","unstructured":"O\u2019Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 22, 118\u2013131 (2021).","journal-title":"Lancet Oncol."},{"key":"905_CR296","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1158\/2326-6066.CIR-23-1073","volume":"12","author":"PE Oberstein","year":"2024","unstructured":"Oberstein, P. E. et al. Blockade of IL1beta and PD1 with combination chemotherapy reduces systemic myeloid suppression in metastatic pancreatic cancer with heterogeneous effects in the tumor. Cancer Immunol. Res. 12, 1221\u20131235 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"905_CR297","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1821","author":"PM Grierson","year":"2025","unstructured":"Grierson, P. M. et al. Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1821 (2025).","journal-title":"Clin. Cancer Res."},{"key":"905_CR298","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening, T. M. et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 17, 651\u2013662 (2016).","journal-title":"Lancet Oncol."},{"key":"905_CR299","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10637-019-00830-3","volume":"38","author":"M Noel","year":"2020","unstructured":"Noel, M. et al. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest. N. Drugs 38, 800\u2013811 (2020).","journal-title":"Invest. N. Drugs"},{"key":"905_CR300","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1245\/s10434-013-3390-y","volume":"21","author":"Y Homma","year":"2014","unstructured":"Homma, Y. et al. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 21, 670\u2013676 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"905_CR301","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007586","author":"MHG Katz","year":"2023","unstructured":"Katz, M. H. G. et al. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2023-007586 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"905_CR302","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1158\/2159-8290.CD-15-0827","volume":"6","author":"AJ Gunderson","year":"2016","unstructured":"Gunderson, A. J. et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov. 6, 270\u2013285 (2016). This study was an early indicator of the functional importance of B cells in pancreatic tumorigenesis, mediated in part by BTK.","journal-title":"Cancer Discov."},{"key":"905_CR303","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.annonc.2021.01.070","volume":"32","author":"M Tempero","year":"2021","unstructured":"Tempero, M. et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann. Oncol. 32, 600\u2013608 (2021).","journal-title":"Ann. Oncol."},{"key":"905_CR304","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-20-2974","volume":"27","author":"L Zheng","year":"2021","unstructured":"Zheng, L. et al. Vaccine-induced intratumoral lymphoid aggregates correlate with survival following treatment with a neoadjuvant and adjuvant vaccine in patients with resectable pancreatic adenocarcinoma. Clin. Cancer Res. 27, 1278\u20131286 (2021).","journal-title":"Clin. Cancer Res."},{"key":"905_CR305","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-19-3978","volume":"26","author":"T Tsujikawa","year":"2020","unstructured":"Tsujikawa, T. et al. Evaluation of cyclophosphamide\/GVAX pancreas followed by listeria-mesothelin (CRS-207) with or without nivolumab in patients with pancreatic cancer. Clin. Cancer Res. 26, 3578\u20133588 (2020).","journal-title":"Clin. Cancer Res."},{"key":"905_CR306","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","volume":"26","author":"AA Wu","year":"2020","unstructured":"Wu, A. A. et al. A phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer. Clin. Cancer Res. 26, 5129\u20135139 (2020).","journal-title":"Clin. Cancer Res."},{"key":"905_CR307","doi-asserted-by":"publisher","first-page":"111569","DOI":"10.1016\/j.isci.2024.111569","volume":"28","author":"JM Montagne","year":"2025","unstructured":"Montagne, J. M. et al. CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer clinical trial. iScience 28, 111569 (2025).","journal-title":"iScience"},{"key":"905_CR308","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39196-9","volume":"14","author":"T Heumann","year":"2023","unstructured":"Heumann, T. et al. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nat. Commun. 14, 3650 (2023).","journal-title":"Nat. Commun."},{"key":"905_CR309","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med. 30, 531\u2013542 (2024).","journal-title":"Nat. Med."},{"key":"905_CR310","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1158\/2159-8290.CD-24-0740","volume":"14","author":"A Singhal","year":"2024","unstructured":"Singhal, A. et al. A classical epithelial state drives acute resistance to KRAS inhibition in pancreatic cancer. Cancer Discov. 14, 2122\u20132134 (2024).","journal-title":"Cancer Discov."},{"key":"905_CR311","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly, J. et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 14, 2135\u20132161 (2024).","journal-title":"Cancer Discov."},{"key":"905_CR312","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","volume":"30","author":"M Wehrli","year":"2024","unstructured":"Wehrli, M. et al. Mesothelin CAR T cells secreting anti-FAP\/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma. Clin. Cancer Res. 30, 1859\u20131877 (2024).","journal-title":"Clin. Cancer Res."},{"key":"905_CR313","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191805","author":"S Bhattacharyya","year":"2020","unstructured":"Bhattacharyya, S. et al. Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20191805 (2020).","journal-title":"J. Exp. Med."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41568-025-00905-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-025-00905-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-025-00905-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T12:02:09Z","timestamp":1774872129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41568-025-00905-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":313,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1038\/s41568-025-00905-9","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"17 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}